Your browser doesn't support javascript.
loading
Metformin and tuberculosis risk in elderly patients with diabetes mellitus.
Park, S; Yang, B R; Song, H J; Jang, S H; Kang, D Y; Park, B-J.
Affiliation
  • Park S; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Department of Family Medicine, Seoul Metropolitan Eunpyeong Hospital, Seoul.
  • Yang BR; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Department of Preventive Medicine, Seoul National University College of Medicine, Seoul.
  • Song HJ; Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang-si.
  • Jang SH; Division of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang-si.
  • Kang DY; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Drug Safety Monitoring Center, Seoul National University Hospital, Seoul, Republic of Korea.
  • Park BJ; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul.
Int J Tuberc Lung Dis ; 23(8): 924-930, 2019 08 01.
Article in En | MEDLINE | ID: mdl-31533883
ABSTRACT

SETTING:

Tuberculosis (TB) and diabetes mellitus (DM) remain global health concerns. Metformin has recently received attention for its anti-tuberculosis effects.

OBJECTIVE:

To evaluate the risk of TB development in elderly DM patients treated with metformin compared with sulfonylureas.

DESIGN:

We performed a retrospective cohort study using the National Health Insurance Service-Senior database. The participants were type-2 DM (T2DM) patients aged ≥60 years between 1 January 2003 and 31 December 2013. We matched each metformin user to a sulfonylurea user using a propensity score. A Cox proportional hazards model was used to compare the risk of TB in metformin and sulfonylurea users.

RESULTS:

After propensity score matching, 12,582 patients were in each group. The TB incidence was 280.2/100 000 person-years (py) for metformin users and 394.5/100 000 py for sulfonylurea users. Metformin users had a lower risk of TB development than sulfonylurea users (adjusted hazard ratio 0.74, 95%CI 0.58-0.95), and the results were stronger for male participants. A dose-response relationship between metformin use and TB development was found in both sexes.

CONCLUSION:

Metformin use was associated with a decreased risk of TB development among elderly T2DM patients compared with sulfonylurea use.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Metformin Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Int J Tuberc Lung Dis Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Metformin Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Int J Tuberc Lung Dis Year: 2019 Document type: Article